Ombudsman disagrees with EMA clinical trial data disclosure policy
This article was originally published in SRA
Executive Summary
The European Ombudsman has criticised the European Medicines Agency for turning down requests for access to certain clinical trial data on two anti-obesity drugs – orlistat and rimonabant – on the grounds of protecting drug company commercial interests1,2.
You may also be interested in...
EDQM Sets 2023 Target For Modernizing ‘Certificates Of Suitability’
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
Global Regulators Issue Advice On Clinical Comparability Of Biosimilar MAbs
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Global Pharma Industry Regulators Seek Unified Approach To Remote Inspections
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: